BIP
NVLN

Brandes Investment Partners’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Brandes Investment Partners’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-34,828
Closed -$103K – 153
2018
Q3 		$103K Hold
34,828
– – ﹤0.01% 141
2018
Q2 		$128K Hold
34,828
– – ﹤0.01% 138
2018
Q1 		$122K Hold
34,828
– – ﹤0.01% 137
2017
Q4 		$109K Hold
34,828
– – ﹤0.01% 140
2017
Q3 		$245K Hold
34,828
– – 0.01% 129
2017
Q2 		$321K Hold
34,828
– – 0.01% 137
2017
Q1 		$374K Sell
34,828
-3,754
-10% -$38.4K 0.01% 128
2016
Q4 		$325K Buy
+38,582
New +$342K ﹤0.01% 135

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brandes Investment Partners's NVLN Position: Q4 2018 in Review

Brandes Investment Partners sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2018, closing a stake of 34,828 shares — an estimated $103K sold.

Brandes Investment Partners first reported a position in NVLN in Q4 2016 and held it in 8 quarters. The position peaked at $374K in Q1 2017. 36 funds tracked by Wall St. Rank hold NVLN as of Q4 2018.

  • Brandes Investment Partners reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2018 after selling out during the quarter.
  • Brandes Investment Partners sold 34,828 Novelion Therapeutics Inc. Common Shares shares in Q4 2018, an estimated $103K.
  • Brandes Investment Partners first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 8 quarters.
  • Brandes Investment Partners's Novelion Therapeutics Inc. Common Shares position peaked at $374K in Q1 2017.
  • 36 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2018.

Based on Brandes Investment Partners's 13F filing for Q4 2018, filed 11 Feb 2019.